Fifty per cent of patients with Head and Neck (H&N) cancer have a locoregional or distant relapse after the first line of treatment which is responsible for a poor overall survival rate ranging from 40% to 50%. Conventional second line treatment options have a low response rate (4% to 14%), with a mean survival of only 10 months, accompanied by toxicity rates around 70% to